MA26750A1 - Procede pour la preparation d'inhibiteurs de 5-lipoxygenase ayant divers systemes heterocycliques - Google Patents

Procede pour la preparation d'inhibiteurs de 5-lipoxygenase ayant divers systemes heterocycliques

Info

Publication number
MA26750A1
MA26750A1 MA26053A MA26053A MA26750A1 MA 26750 A1 MA26750 A1 MA 26750A1 MA 26053 A MA26053 A MA 26053A MA 26053 A MA26053 A MA 26053A MA 26750 A1 MA26750 A1 MA 26750A1
Authority
MA
Morocco
Prior art keywords
preparation
lipoxygenase inhibitors
various heterocyclic
heterocyclic systems
systems
Prior art date
Application number
MA26053A
Other languages
English (en)
Inventor
Elizabeth Hnatow Megan
Norris Timothy
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of MA26750A1 publication Critical patent/MA26750A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D309/04—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyridine Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Catalysts (AREA)

Abstract

"Procédé pour la préparation d'inhibiteurs de 5-lipoxygénase ayant divers systèmes hétérocycliques" L'invention concerne un procédé pour la préparation d'un composé de formule (1.3.0) : dans laquelle le groupement azoté est un groupe N-hétérocyclique, monocyclique ou bicyclique benzo-condensé déficient en électrons, à 2 atomes d'azote. Elle concerne également la préparation de la matière de départ. Application : préparation d'inhibiteurs de 5-lipoxygénase ayant divers systèmes cycliques hétérocycliques.
MA26053A 1999-08-31 2000-08-30 Procede pour la preparation d'inhibiteurs de 5-lipoxygenase ayant divers systemes heterocycliques MA26750A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US15161099P 1999-08-31 1999-08-31

Publications (1)

Publication Number Publication Date
MA26750A1 true MA26750A1 (fr) 2004-12-20

Family

ID=22539510

Family Applications (1)

Application Number Title Priority Date Filing Date
MA26053A MA26750A1 (fr) 1999-08-31 2000-08-30 Procede pour la preparation d'inhibiteurs de 5-lipoxygenase ayant divers systemes heterocycliques

Country Status (33)

Country Link
EP (1) EP1081144A3 (fr)
JP (1) JP2001106686A (fr)
KR (1) KR20010050274A (fr)
CN (1) CN1286251A (fr)
AP (1) AP2000001909A0 (fr)
AR (1) AR022650A1 (fr)
AU (1) AU5370200A (fr)
BG (1) BG104730A (fr)
BR (1) BR0003888A (fr)
CA (1) CA2316748A1 (fr)
CO (1) CO5180623A1 (fr)
CZ (1) CZ20003159A3 (fr)
EA (1) EA200000803A3 (fr)
EE (1) EE200000513A (fr)
GT (1) GT200000144A (fr)
HR (1) HRP20000565A2 (fr)
HU (1) HUP0003437A3 (fr)
ID (1) ID27128A (fr)
IL (1) IL138089A0 (fr)
IS (1) IS5604A (fr)
MA (1) MA26750A1 (fr)
NO (1) NO20004312L (fr)
NZ (1) NZ506633A (fr)
OA (1) OA11451A (fr)
PA (1) PA8499601A1 (fr)
PE (1) PE20010523A1 (fr)
PL (1) PL342280A1 (fr)
SG (1) SG87145A1 (fr)
SK (1) SK12862000A3 (fr)
SV (1) SV2002000160A (fr)
TN (1) TNSN00176A1 (fr)
TR (1) TR200002530A2 (fr)
UY (1) UY26315A1 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1627644A4 (fr) * 2003-05-23 2012-01-18 Hisamitsu Pharmaceutical Co Preparation administree par voie percutanee externe et contenant une substance medicamenteuse anti-inflammatoire non steroidienne et un inhibiteur de production d'interleukine-1$g(a)
EP1834953A1 (fr) * 2006-03-14 2007-09-19 Ranbaxy Laboratories Limited Dérivés de tetrahydropyrane comme Inhibiteurs de la 5- lipoxygénase
CN103980312B (zh) * 2014-05-27 2016-09-07 广州大学 一种n杂环双膦配体及其合成方法
WO2025038927A1 (fr) * 2023-08-16 2025-02-20 Raythera, Inc. Modulateurs de l'activité du tnf alpha et leurs utilisations

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SK281577B6 (sk) * 1994-10-18 2001-05-10 Pfizer Inc. Heterocyklické zlúčeniny a farmaceutický prostriedok na ich báze

Also Published As

Publication number Publication date
TNSN00176A1 (fr) 2005-11-10
SV2002000160A (es) 2002-01-23
HUP0003437A3 (en) 2002-08-28
SK12862000A3 (sk) 2002-02-05
BG104730A (en) 2001-09-28
AU5370200A (en) 2001-03-08
HUP0003437A2 (hu) 2001-06-28
EA200000803A2 (ru) 2001-04-23
PA8499601A1 (es) 2002-02-21
TR200002530A2 (tr) 2001-04-20
CA2316748A1 (fr) 2001-02-28
CO5180623A1 (es) 2002-07-30
EE200000513A (et) 2001-04-16
EA200000803A3 (ru) 2001-06-25
EP1081144A2 (fr) 2001-03-07
NO20004312D0 (no) 2000-08-30
AR022650A1 (es) 2002-09-04
NO20004312L (no) 2001-03-01
BR0003888A (pt) 2001-12-11
GT200000144A (es) 2002-02-20
CZ20003159A3 (cs) 2001-12-12
JP2001106686A (ja) 2001-04-17
KR20010050274A (ko) 2001-06-15
CN1286251A (zh) 2001-03-07
HU0003437D0 (en) 2000-08-30
OA11451A (en) 2003-12-08
HRP20000565A2 (en) 2001-06-30
PL342280A1 (en) 2001-03-12
UY26315A1 (es) 2001-04-30
NZ506633A (en) 2001-12-21
AP2000001909A0 (en) 2000-09-30
PE20010523A1 (es) 2001-04-28
SG87145A1 (en) 2002-03-19
IS5604A (is) 2001-03-01
EP1081144A3 (fr) 2001-04-11
ID27128A (id) 2001-03-01
IL138089A0 (en) 2001-10-31

Similar Documents

Publication Publication Date Title
LU91339I2 (fr) Darunavir ou un sel, ester ou promédicament pharmaceutiquement acceptable de celui-ci (prezista)
EP1090908A3 (fr) Derives de cyclobutane utilisés comme inhibiteurs de la protéine farnesyltransferase
DK1104760T3 (da) Sulfamoylheteroarylpyrazolforbindelser som anti-inflammatoriske/analgetiske midler
EP1206937A4 (fr) Preparations de nitroimidazole a usage externe pour traiter la dermatose
IS2750B (is) Leiðarafesting
ES2164716T3 (es) Compuestos triciclicos de carbamato utiles para inhibir la funcion de la proteina-g y para el tratamiento de enfermedades proliferativas.
NO931795L (no) Dobbeltvirkende inhibitorer
BR9401482A (pt) 1H-Indol-3-acetamida, formulação farmacêutica, utilização de um composto e processo para a preparação de 1h-indol-3-acetamida
ES2070660A1 (es) Un procedimiento para la preparacion de 2,5-damino-3-hidroxihexanos sustituidos, utiles como inhibidores de proteasas retrovirales.
BG101422A (bg) Бензоксазолни производни като бронхоразширяващи средства
DK0727419T3 (da) Mellemprodukter til fremstilling af forbindelser, som inhiberer retroviral protease
ES2138667T3 (es) Productos intermediarios para la preparacion de un 2,5-diamino-3-hidroxihexano sustituido.
BR9401484A (pt) Hidrazida de ácido 1h-indol-3-acético e formulação farmacêutica
BR0011121A (pt) Compostos antibacterianos
DK1104759T3 (da) Heteroarylphenylpyrazolforbindelser som antiinflammatoriske/analgetiske midler
AU6518998A (en) Morphinane derivatives and medicinal use thereof
FR2359830A1 (fr) 6-alcoyl-pyrimidines utilisables comme medicament, notamment contre la malaria
KR0148213B1 (en) Phenyla lkan(en)oic acid and pharmaceutical composition comprising the same
WO2003053971A8 (fr) Antiviraux a base de pyridoquinoxaline
BR0209901A (pt) Processos para a sìntese de derivados de 2,3-dihidro-1,4-dioxino-[2,3-f] quinolina
DK0613687T3 (da) Anvendelse af pregnanderivat til behandling af tumorer
ES2062094T3 (es) Derivados del acido parabanico y composiciones farmaceuticas que los contienen.
EP0302967A3 (en) Quinazoline derivative, processes for its production, and cerebral dysfunction remedying agent comprising it as active ingredient
FI952420A0 (fi) Glukopyranosidibentsotiofeenit
TNSN00176A1 (fr) Procede pour la preparation d'inhibiteurs de 5-lipoxygenase ayant divers systemes heterocycliques